A Systematic Review of Oxymorphone in the Management of Chronic Pain

Journal of Pain and Symptom Management

Volumn 39, Issue 2, 2010, Pages 296-308

  Mayyas, Fadia ^a   Fayers, Peter ^a,b,d   Kaasa, Stein ^a,b,c   Dale, Ola ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

cancer; chronic pain; extended release; low back pain; opioids; osteoarthritis; Oxymorphone; systematic review

Indexed keywords

MORPHINE; OPANA; OPANA ER; OXYCODONE; OXYMORPHONE; PLACEBO; TIMERX; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIA; BACKACHE; CANCER PAIN; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC PAIN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; EVALUATION; EVIDENCE BASED PRACTICE; EXTERNAL VALIDITY; HEADACHE; HUMAN; INTERNAL VALIDITY; LOW BACK PAIN; MEDICAL ETHICS; MEDICAL RESEARCH; META ANALYSIS; NAUSEA; OSTEOARTHRITIS; PANCREATITIS; PRURITUS; PUBLISHING; QUALITY CONTROL; RESEARCH ETHICS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STANDARD; SYSTEMATIC REVIEW; THORAX PAIN; URINE RETENTION; VOMITING;

ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; LOW BACK PAIN; NEOPLASMS; OSTEOARTHRITIS; OXYMORPHONE; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 75749131983     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.07.010     Document Type: Review

References (47)

1. Kalso E., Allan L., Dellemijn P.L., et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 7 (2003) 381-386
2. Kalso E., Edwards J.E., Moore R.A., and McQuay H.J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112 (2004) 372-380
3. Bell R.F., Wisloff T., Eccleston C., and Kalso E. Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. Br J Cancer 94 (2006) 1559-1567
4. Caldwell J.R., Rapoport R.J., Davis J.C., et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 23 (2002) 278-291
5. Maier C., Hildebrandt J., Klinger R., Henrich-Eberl C., and Lindena G. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain-results of a double-blind placebo-controlled trial (MONTAS). Pain 97 (2002) 223-233
6. Roth S.H., Fleischmann R.M., Burch F.X., et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 160 (2000) 853-860
7. Hanks G.W., Conno F., Cherny N., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84 (2001) 587-593
8. Cherny N.J., Chang V., Frager G., et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76 (1995) 1283-1293
9. Galer B.S., Coyle N., Pasternak G.W., and Portenoy R.K. Individual variability in the response to different opioids: report of five cases. Pain 49 (1992) 87-91
10. Crews J.C., Sweeney N.J., and Denson D.D. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 72 (1993) 2266-2272
11. Sinatra R.S., and Harrison D.M. A comparison of oxymorphone and fentanyl as narcotic supplements in general anesthesia. J Clin Anesth 1 (1989) 253-258
12. Madsen H., Enggaard T.P., Hansen L.L., Klitgaard N.A., and Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 69 (2001) 41-47
13. Classen D.C., Pestotnik S.L., Evans R.S., Lloyd J.F., and Burke J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277 (1997) 301-306
14. Johnson J.A., and Bootman J.L. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 155 (1995) 1949-1956
15. Inturrisi C.E. Clinical pharmacology of opioids for pain. Clin J Pain 18 (2002) S3-S13
16. Adams M.P., and Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 24 (2004) 468-476
17. Sloan P.A., and Barkin R.L. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag 4 (2008) 131-144
18. Sloan P. Review of oral oxymorphone in the management of pain. Ther Clin Risk Manag 4 (2008) 777-787
19. Prommer E. Oxymorphone: a review. Support Care Cancer 14 (2006) 109-115
20. Chamberlin K.W., Cottle M., Neville R., and Tan J. Oral oxymorphone for pain management. Ann Pharmacother 41 (2007) 1144-1152
21. Eddy N.B., and Lee Jr. L.E. The analgesic equivalence to morphine and relative side action liability of oxymorphone (14-hydroxydihydro morphinone). J Pharmacol Exp Ther 125 (1959) 116-121
22. Sinatra R.S., Hyde N.H., and Harrison D.M. Oxymorphone revisited. J Clin Anesth 7 (1988) 209-215
23. Adams M.P., and Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D 6 (2005) 91-99
24. Gimbel J., and Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 99 (2004) 1472-1477
25. Cone E.J., Darwin W.D., Buchwald W.F., and Gorodetzky C.W. Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 11 (1983) 446-450
26. Adams M., Pieniaszek Jr. H.J., Gammaitoni A.R., and Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 45 (2005) 337-345
27. Hermens J.M., Ebertz J.M., Hanifin J.M., and Hirshman C.A. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 62 (1985) 124-129
28. Sloan P., Slatkin N., and Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 13 (2005) 57-65
29. Gabrail N.Y., Dvergsten C., and Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 20 (2004) 911-918
30. Matsumoto A.K., Babul N., and Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 6 (2005) 357-366
31. Hale M.E., Dvergsten C., and Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 6 (2005) 21-28
32. Kivitz A., Ma C., Ahdieh H., and Galer B.S. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 28 (2006) 352-364
33. Hale M.E., Ahdieh H., Ma T., and Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 8 (2007) 175-184
34. Katz N., Rauck R., Ahdieh H., et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 23 (2007) 117-128
35. McIlwain H., and Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther 12 (2005) 106-112
36. Beaver W.T., Wallenstein S.L., Houde R.W., and Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 17 (1977) 186-198
37. Centre for Reviews and Dissemination (CRD). Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. CRD report no. 4. 2nd ed. (2001), University of York, York, UK
38. Heier H.E., Bugge W., Hjelmeland K., et al. Transfusion vs. alternative treatment modalities in acute bleeding: a systematic review. Acta Anaesthesiol Scand 50 (2006) 920-931
39. Harbour R., and Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 323 (2001) 334-336
40. Review Manager (Rev Man), version 5.0 (2008), The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark
41. Matsumoto A.K. Oral extended-release oxymorphone: a new choice for chronic pain relief. Expert Opin Pharmacother 8 (2007) 1515-1527
42. Slavin R.E. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 48 (1995) 9-18
43. Farrar J.T., Young Jr. J.P., LaMoreaux L., Werth J.L., and Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001) 149-158
44. Michels K.B., and Rothman K.J. Update on unethical use of placebos in randomised trials. Bioethics 17 (2003) 188-204
45. Rothman K.J., and Michels K.B. The continuing unethical use of placebo controls. N Engl J Med 331 (1994) 394-398
46. Hasselstrom J., and Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 24 (1993) 344-354
47. ® (oxymorphone hydrochloride). Full prescribing information (2006), Endo Pharmaceuticals Inc., Chadds Ford, PA